Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.

The result showed a trend toward higher rates of MPR in patients with PD-L1 CPS ≥1 (66.7% vs 37.5%; p=0.23, figure 2E ), although patient survival, such as RFS and OS, were not stratified by PD-L1 expression ( online supplemental figure 2 ), likely related to the immaturity of the data.

also in 53,322 other papers